{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:32:47Z","timestamp":1793035967760,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["NIA U01AG066623-01"],"award-info":[{"award-number":["NIA U01AG066623-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Decreased cerebral blood flow and systemic inflammation during heart failure (HF) increase the risk for vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer disease-related dementias (ADRD). We previously demonstrated that PNA5, a novel glycosylated angiotensin 1\u20137 (Ang-(1\u20137)) Mas receptor (MasR) agonist peptide, is an effective therapy to rescue cognitive impairment in our preclinical model of VCID. Neurofilament light (NfL) protein concentration is correlated with cognitive impairment and elevated in neurodegenerative diseases, hypoxic brain injury, and cardiac disease. The goal of the present study was to determine (1) if treatment with Ang-(1\u20137)\/MasR agonists can rescue cognitive impairment and decrease VCID-induced increases in NfL levels as compared to HF-saline treated mice and, (2) if NfL levels correlate with measures of cognitive function and brain cytokines in our VCID model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>VCID was induced in C57BL\/6 male mice via myocardial infarction (MI). At 5 weeks post-MI, mice were treated with daily subcutaneous injections for 24\u00a0days, 5 weeks after MI, with PNA5 or angiotensin 1\u20137 (500 microg\/kg\/day or 50 microg\/kg\/day) or saline (<jats:italic>n<\/jats:italic>\u2009=\u200915\/group). Following the 24-day treatment protocol, cognitive function was assessed using the Novel Object Recognition (NOR) test. Cardiac function was measured by echocardiography and plasma concentrations of NfL were quantified using a Quanterix Simoa assay. Brain and circulating cytokine levels were determined with a MILLIPLEX MAP Mouse High Sensitivity Multiplex Immunoassay. Treatment groups were compared via ANOVA, significance was set at <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Treatment with Ang-(1\u20137)\/MasR agonists reversed VCID-induced cognitive impairment and significantly decreased NfL levels in our mouse model of VCID as compared to HF-saline treated mice. Further, NfL levels were significantly negatively correlated with cognitive scores and the concentrations of multiple pleiotropic cytokines in the brain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These data show that treatment with Ang-(1\u20137)\/MasR agonists rescues cognitive impairment and decreases plasma NfL relative to HF-saline-treated animals in our VCID mouse model. Further, levels of NfL are significantly negatively correlated with cognitive function and with several brain cytokine concentrations. Based on these preclinical findings, we propose that circulating NfL might be a candidate for a prognostic biomarker for VCID and may also serve as a pharmacodynamic\/response biomarker for therapeutic target engagement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-021-02281-1","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:37:18Z","timestamp":1634330238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Neurofilament light: a possible prognostic biomarker for treatment of vascular contributions to cognitive impairment and dementia"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4400-2529","authenticated-orcid":false,"given":"Christina","family":"Hoyer-Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Konhilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Polt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian P.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Billheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"issue":"9","key":"2281_CR1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/archinte.166.9.1003","volume":"166","author":"C Qiu","year":"2006","unstructured":"Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: A population-based cohort study. Arch Intern Med. 2006;166(9):1003\u20138.","journal-title":"Arch Intern Med"},{"key":"2281_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2017.01.005","author":"C Audia","year":"2017","unstructured":"Audia C, Santos Y, Snyder PJ, Wu W-C, Zhang M, Echeverria A, et al. Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement. 2017. https:\/\/doi.org\/10.1016\/j.dadm.2017.01.005.","journal-title":"Alzheimers Dement"},{"key":"2281_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10571-016-0334-7","volume":"36","author":"RA Corriveau","year":"2016","unstructured":"Corriveau RA, Bosetti F, Emr M, Gladman JT, Koenig JI, Moy CS, et al. The science of vascular contributions to cognitive impairment and dementia (vcid): a framework for advancing research priorities in the cerebrovascular biology of cognitive decline. Cell Mol Neurobiol. 2016;36:281\u20138.","journal-title":"Cell Mol Neurobiol"},{"issue":"5","key":"2281_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.bbadis.2016.02.010","volume":"1862","author":"M Mp","year":"2016","unstructured":"Mp M, Ra C, Dm W. Vascular contributions to cognitive impairment and dementia (VCID). Biochim Biophys Acta. 2016;1862(5):857\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2281_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-005-0078-4","volume":"57","author":"KE Rodgers","year":"2006","unstructured":"Rodgers KE, Oliver J, DiZerega GS. Phase I\/II dose escalation study of angiotensin 1\u20137 [A(1\u20137)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. 2006;57(5):559\u201368.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2281_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1037\/bne0000182","volume":"131","author":"M Hay","year":"2017","unstructured":"Hay M, Vanderah TW, Samareh-Jahani F, Constantopoulos E, Uprety AR, Barnes CA, et al. Cognitive impairment in heart failure: a protective role for angiotensin-(1\u20137). Behav Neurosci. 2017;131(1):99\u2013114.","journal-title":"Behav Neurosci"},{"key":"2281_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/jpet.118.254854","volume":"369","author":"M Hay","year":"2019","unstructured":"Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, et al. A novel angiotensin-(1\u20137) glycosylated mas receptor agonist for treating vascular cognitive impairment and inflammation-related memory dysfunction. J Pharmacol Exp Ther. 2019;369:9\u201325.","journal-title":"J Pharmacol Exp Ther"},{"issue":"18","key":"2281_CR8","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1111\/bph.12770","volume":"171","author":"T Jiang","year":"2014","unstructured":"Jiang T, Yu JT, Zhu XC, Zhang QQ, Tan MS, Cao L, et al. Angiotensin-(1\u20137) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas\/eNOS-dependent pathway. Br J Pharmacol. 2014;171(18):4222\u201332.","journal-title":"Br J Pharmacol"},{"key":"2281_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000196268.08909.fb","author":"CM Ferrario","year":"2006","unstructured":"Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1\u20137): an evolving story in cardiovascular regulation. Hypertension. 2006. https:\/\/doi.org\/10.1161\/01.HYP.0000196268.08909.fb.","journal-title":"Hypertension"},{"key":"2281_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.06.030","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron. 2016. https:\/\/doi.org\/10.1016\/j.neuron.2016.06.030.","journal-title":"Neuron"},{"issue":"1","key":"2281_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","volume":"7","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortob\u00e1gyi T, H\u00f6glund K, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7(1):5.","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"2281_CR12","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00415-019-09398-7","volume":"266","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L, et al. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. J Neurol. 2019;266(9):2157\u201363.","journal-title":"J Neurol"},{"issue":"8","key":"2281_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/ene.12579","volume":"22","author":"LM Villar","year":"2015","unstructured":"Villar LM, Pic\u00f3n C, Costa-Frossard L, Alenda R, Garc\u00eda-Caldentey J, Espi\u00f1o M, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol. 2015;22(8):1169\u201375.","journal-title":"Eur J Neurol"},{"issue":"20","key":"2281_CR14","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1089\/neu.2019.6375","volume":"36","author":"E Thelin","year":"2019","unstructured":"Thelin E, Al Nimer F, Frostell A, Zetterberg H, Blennow K, Nystr\u00f6m H, et al. A Serum protein biomarker panel improves outcome prediction in human traumatic brain injury. J Neurotrauma. 2019;36(20):2850\u201362.","journal-title":"J Neurotrauma"},{"issue":"6","key":"2281_CR15","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000009983","volume":"95","author":"P Shahim","year":"2020","unstructured":"Shahim P, Politis A, van der Merwe A, Moore B, Chou YY, Pham DL, et al. Neurofilament light as a biomarker in traumatic brain injury. Neurology. 2020;95(6):e610\u201322.","journal-title":"Neurology"},{"key":"2281_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fneur.2020.00448","volume":"11","author":"HH Nielsen","year":"2020","unstructured":"Nielsen HH, Soares CB, H\u00f8gedal SS, Madsen JS, Hansen RB, Christensen AA, et al. Acute neurofilament light chain plasma levels correlate with stroke severity and clinical outcome in ischemic stroke patients. Front Neurol. 2020;11:11.","journal-title":"Front Neurol"},{"key":"2281_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivaa264","author":"S Wiberg","year":"2020","unstructured":"Wiberg S, Holmgaard F, Blennow K, Nilsson JC, Kjaergaard J, Wanscher M, et al. Associations between mean arterial pressure during cardiopulmonary bypass and biomarkers of cerebral injury in patients undergoing cardiac surgery: secondary results from a randomized controlled trial. Interact Cardiovasc Thorac Surg. 2020. https:\/\/doi.org\/10.1093\/icvts\/ivaa264.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"2","key":"2281_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0008-6363(99)00274-6","volume":"45","author":"XM Gao","year":"2000","unstructured":"Gao XM, Dart AM, Dewar E, Jennings G, Du XJ. Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice. Cardiovasc Res. 2000;45(2):330\u20138.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2281_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","volume":"31","author":"A Ennaceur","year":"1988","unstructured":"Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res. 1988;31(1):47\u201359.","journal-title":"Behav Brain Res"},{"key":"2281_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61345-7","author":"JA Rumberger","year":"1994","unstructured":"Rumberger JA. Ventricular dilatation and remodeling after myocardial infarction. Mayo Clinic Proc. 1994. https:\/\/doi.org\/10.1016\/S0025-6196(12)61345-7.","journal-title":"Mayo Clinic Proc"},{"issue":"5","key":"2281_CR21","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbadis.2015.12.023","volume":"1862","author":"A Kapasi","year":"2016","unstructured":"Kapasi A, Schneider JA. Vascular contributions to cognitive impairment, clinical Alzheimer\u2019s disease, and dementia in older persons. Biochim Biophys Acta Mol Basis Dis. 2016;1862(5):878\u201386.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6","key":"2281_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jalz.2011.08.008","volume":"8","author":"JB Toledo","year":"2012","unstructured":"Toledo JB, Toledo E, Weiner MW, Jack CR, Jagust W, Lee VMY, et al. Cardiovascular risk factors, cortisol, and amyloid-\u03b2 deposition in Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimer\u2019s Dement. 2012;8(6):483\u20139.","journal-title":"Alzheimer\u2019s Dement."},{"issue":"12","key":"2281_CR23","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1093\/brain\/aws271","volume":"135","author":"M Yarchoan","year":"2012","unstructured":"Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(12):3749\u201356.","journal-title":"Brain"},{"issue":"5","key":"2281_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21073","volume":"61","author":"M van Oijen","year":"2007","unstructured":"van Oijen M, de Jong FJ, Witteman JCM, Hofman A, Koudstaal PJ, Breteler MMB. Atherosclerosis and risk for dementia. Ann Neurol. 2007;61(5):403\u201310.","journal-title":"Ann Neurol"},{"issue":"10","key":"2281_CR25","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1161\/STR.0000000000000148","volume":"48","author":"PB Gorelick","year":"2017","unstructured":"Gorelick PB, Furie KL, Iadecola C, Smith EE, Waddy SP, Lloyd-Jones DM, et al. Defining optimal brain health in adults: a presidential advisory from the American Heart Association\/American Stroke Association. Stroke. 2017;48(10):e284-303.","journal-title":"Stroke"},{"issue":"1","key":"2281_CR26","first-page":"69","volume":"7","author":"CY Santos","year":"2017","unstructured":"Santos CY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement. 2017;7(1):69\u201387.","journal-title":"Alzheimers Dement"},{"key":"2281_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00065","author":"I Canobbio","year":"2015","unstructured":"Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer\u2019s disease. Front Cell Neurosci. 2015. https:\/\/doi.org\/10.3389\/fncel.2015.00065.","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"2281_CR28","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1007\/s12035-015-9319-7","volume":"53","author":"C Janota","year":"2015","unstructured":"Janota C, Lemere CA, Brito MA. Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer\u2019s Disease. Mol Neurobiol. 2015;53(6):3793\u2013811.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"2281_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jalz.2018.07.222","volume":"15","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. Vascular dysfunction\u2014the disregarded partner of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2019;15(1):158\u201367.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"5","key":"2281_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.bbadis.2015.12.009","volume":"1862","author":"AM Helman","year":"2016","unstructured":"Helman AM, Murphy MP. Vascular cognitive impairment: Modeling a critical neurologic disease in vitro and in vivo. Biochim Biophys Acta Mol Basis Dis. 2016;1862(5):975\u201382.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"4","key":"2281_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1212\/WNL.57.4.714","volume":"57","author":"C Wentzel","year":"2001","unstructured":"Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan DB, Feldman H, et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology. 2001;57(4):714\u20136.","journal-title":"Neurology"},{"issue":"5\u20136","key":"2281_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000095751","volume":"22","author":"GYR Hsiung","year":"2006","unstructured":"Hsiung GYR, Donald A, Grand J, Black SE, Bouchard RW, Gauthier SG, et al. Outcomes of cognitively impaired not demented at 2 years in the Canadian cohort study of cognitive impairment and related dementias. Dement Geriatr Cogn Disord. 2006;22(5\u20136):413\u201320.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"2281_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Weiner MW, Aisen P, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2281_CR34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"2\u20133","key":"2281_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000101843","volume":"4","author":"A Petzold","year":"2007","unstructured":"Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis. 2007;4(2\u20133):185\u201394.","journal-title":"Neurodegener Dis"},{"issue":"5","key":"2281_CR36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1212\/WNL.52.5.1090","volume":"52","author":"LE Rosengren","year":"1999","unstructured":"Rosengren LE, Karlsson JE, Sj\u00f6gren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999;52(5):1090\u20133.","journal-title":"Neurology"},{"issue":"21","key":"2281_CR37","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck T, Farahmand B, Bartlett JW, Ros\u00e9n C, Mattsson N, N\u00e4gga K, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21):1945\u201353.","journal-title":"Neurology"},{"key":"2281_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6612871","author":"W Ma","year":"2020","unstructured":"Ma W, Zhang J, Xu J, Feng D, Wang X, Zhang F. Elevated levels of serum neurofilament light chain associated with cognitive impairment in vascular dementia. Dis Markers. 2020. https:\/\/doi.org\/10.1155\/2020\/6612871.","journal-title":"Dis Markers"},{"key":"2281_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112812","author":"V Cipollini","year":"2019","unstructured":"Cipollini V, Troili F, Giubilei F. Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application. IJMS. 2019. https:\/\/doi.org\/10.3390\/ijms20112812.","journal-title":"IJMS"},{"key":"2281_CR40","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools). Silver Spring (MD): Food and Drug Administration (US); 2016-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/ Co-published by National Institutes of Health (US), Bethesda (MD)."},{"issue":"10","key":"2281_CR41","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007\u201315.","journal-title":"Neurology"},{"issue":"10","key":"2281_CR42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","volume":"95","author":"R Kapoor","year":"2020","unstructured":"Kapoor R, Smith KE, Allegretta M, Arnold DL, Carroll W, Comabella M, et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology. 2020;95(10):436\u201344.","journal-title":"Neurology"},{"key":"2281_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00338","author":"KN Varhaug","year":"2019","unstructured":"Varhaug KN, Torkildsen \u00d8, Myhr KM, Vedeler CA. Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol. 2019. https:\/\/doi.org\/10.3389\/fneur.2019.00338.","journal-title":"Front Neurol"},{"issue":"5","key":"2281_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/jnc.14273","volume":"144","author":"BR Price","year":"2018","unstructured":"Price BR, Norris CM, Sompol P, Wilcock DM. An emerging role of astrocytes in vascular contributions to cognitive impairment and dementia. J Neurochem. 2018;144(5):644\u201350.","journal-title":"J Neurochem"},{"key":"2281_CR45","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fnagi.2018.00350","volume":"31","author":"BR Price","year":"2018","unstructured":"Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a risk factor for vascular contributions to cognitive impairment and dementia. Front Aging Neurosci. 2018;31:350.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"2281_CR46","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s11357-011-9301-x","volume":"34","author":"JN Trollor","year":"2012","unstructured":"Trollor JN, Smith E, Agars E, Kuan SA, Baune BT, Campbell L, et al. The association between systemic inflammation and cognitive performance in the elderly: The Sydney Memory and Ageing Study. Age (Omaha). 2012;34(5):1295\u2013308.","journal-title":"Age (Omaha)"},{"key":"2281_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/54.7.M357","author":"H Bruunsgaard","year":"1999","unstructured":"Bruunsgaard H. A high plasma concentration of TNF-\u03b1 is associated with dementia in centenarians. J Gerontol Ser A Biol Sci Med Sci. 1999. https:\/\/doi.org\/10.1093\/gerona\/54.7.M357.","journal-title":"J Gerontol Ser A Biol Sci Med Sci."},{"key":"2281_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10741-006-9196-2","volume":"11","author":"A Yndestad","year":"2006","unstructured":"Yndestad A, Dam\u00e5s JK, \u00d8ie E, Yndestad A, et al. Systemic inflammation in heart failure\u2014the whys and wherefores. Hear Fail Rev. 2006;11:83\u201392.","journal-title":"Hear Fail Rev."},{"issue":"3","key":"2281_CR49","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0002-9149(98)00872-8","volume":"83","author":"P Aukrust","year":"1999","unstructured":"Aukrust P, Ueland T, Lien E, Bendtzen K, M\u00fcller F, Andreassen AK, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83(3):376\u201382.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2281_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12974-019-1599-9","volume":"16","author":"KE Salmeron","year":"2019","unstructured":"Salmeron KE, Maniskas ME, Edwards DN, Wong R, Rajkovic I, Trout A, et al. Interleukin 1 alpha administration is neuroprotective and neuro-restorative following experimental ischemic stroke. J Neuroinflammation. 2019;16(1):222.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"2281_CR51","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jnc.13422","volume":"136","author":"K Salmeron","year":"2016","unstructured":"Salmeron K, Aihara T, Redondo-Castro E, Pinteaux E, Bix G. IL-1alpha induces angiogenesis in brain endothelial cells in vitro: Implications for brain angiogenesis after acute injury. J Neurochem. 2016;136(3):573\u201380.","journal-title":"J Neurochem"},{"issue":"3","key":"2281_CR52","first-page":"826","volume":"140","author":"S Alves","year":"2017","unstructured":"Alves S, Churlaud G, Audrain M, Michaelsen-Preusse K, Fol R, Souchet B, et al. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer\u2019s disease mice. Brain. 2017;140(3):826\u201342.","journal-title":"Brain"},{"issue":"9","key":"2281_CR53","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.neurobiolaging.2015.05.013","volume":"36","author":"M Schmitz","year":"2015","unstructured":"Schmitz M, Hermann P, Oikonomou P, Stoeck K, Ebert E, Poliakova T, et al. Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy. Neurobiol Aging. 2015;36(9):2597\u2013606.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2281_CR54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13105-017-0550-8","volume":"73","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Li C, Li D, Zheng Y, Wang J. IL-5 blocks apoptosis and tau hyperphosphorylation induced by A\u03b225\u201335 peptide in PC12 cells. J Physiol Biochem. 2017;73(2):259\u201366.","journal-title":"J Physiol Biochem"},{"issue":"6","key":"2281_CR55","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.4049\/jimmunol.1900909","volume":"204","author":"W Miao","year":"2020","unstructured":"Miao W, Zhao Y, Huang Y, Chen D, Luo C, Su W, et al. IL-13 ameliorates neuroinflammation and promotes functional recovery after traumatic brain injury. J Immunol. 2020;204(6):1486\u201398.","journal-title":"J Immunol"},{"issue":"12","key":"2281_CR56","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.4049\/jimmunol.1102150","volume":"189","author":"BE Morrison","year":"2012","unstructured":"Morrison BE, Marcondes MCG, Nomura DK, Sanchez-Alavez M, Sanchez-Gonzalez A, Saar I, et al. Cutting edge: IL-13R\u03b11 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol. 2012;189(12):5498\u2013502.","journal-title":"J Immunol"},{"key":"2281_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2019.00095","author":"V Cipollini","year":"2019","unstructured":"Cipollini V, Anrather J, Orzi F, Iadecola C. Th17 and cognitive impairment: possible mechanisms of action. Front Neuroanat. 2019. https:\/\/doi.org\/10.3389\/fnana.2019.00095.","journal-title":"Front Neuroanat"},{"key":"2281_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0237-1","author":"Y Bordon","year":"2019","unstructured":"Bordon Y. IL-17: an immune mnemonic. Nat Rev Immunol. 2019. https:\/\/doi.org\/10.1038\/s41577-019-0237-1.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2281_CR59","first-page":"1","volume":"6","author":"C McKimmie","year":"2014","unstructured":"McKimmie C, Michlmayr D. Role of CXCL10 in central nervous system inflammation. Int J Interf Cytokine Mediat Res. 2014;6(1):1.","journal-title":"Int J Interf Cytokine Mediat Res"},{"issue":"1","key":"2281_CR60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-170602","volume":"62","author":"BM Bettcher","year":"2018","unstructured":"Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, et al. CSF and plasma levels of inflammation differentially relate to CNS markers of Alzheimer\u2019s disease pathology and neuronal damage hhs public access. J Alzheimers Dis. 2018;62(1):385\u201397.","journal-title":"J Alzheimers Dis"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-021-02281-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:42:57Z","timestamp":1634330577000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-021-02281-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1186\/s12974-021-02281-1","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"29 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures, handling, and treatments were approved by the institutional Animal Care and Use Committee at the University of Arizona in agreement with the National Institute of Health Guidelines for the care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"COI, Dr. Meredith Hay is the founder of ProNeurogen, Inc. that holds exclusive rights to the clinical development of the Ang-(1\u20137)\/MasR agonists described herein.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}